Japanese drugmaker Sumitomo Pharma (TYO: 4506) and its US subsidiary Sumitomo Pharma America have amended a collaboration with Otsuka Pharmaceuticals (TYO: 4578).
Agreed in late 2021, the deal has seen the firms jointly develop and commercialize four compounds in neuropsychiatry, including ulotaront (SEP-363856) and SEP-4199.
At the time, Otsuka agreed to pay $270 million upfront, with Sumitomo’s US division, then known as Sunovion, also being eligible for milestone payments of up to $620 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze